The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects

British Journal of Cancer

Volumn 80, Issue 5-6, 1999, Pages 629-638

  Hospers, G A P ^a   Eisenhauer, E A ^b   De Vries, E G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Chemoprotection; Glutathione; WR 2721

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; ALKALINE PHOSPHATASE; AMIFOSTINE; ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CHLORMETHINE DERIVATIVE; CISPLATIN; GLUTATHIONE; MAFOSFAMIDE; PACLITAXEL; PRODRUG; THIOL DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; HYPOTENSION; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; RADIATION PROTECTION; REVIEW; VOMITING;

AMIFOSTINE; ANIMALS; ANTIDOTES; ANTINEOPLASTIC AGENTS; FORECASTING; GLUTATHIONE; HUMANS; RADIATION-PROTECTIVE AGENTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032923938     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690404     Document Type: Review

References (81)

1. Aebi S, Assereto R and Lauterburg BH (1991) High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. Eur J Clin Invest 21: 103-110
2. Alberts DS and Noel JK (1995) Cisplatin associated neurotoxicity, can it be prevented? Anticancer Drugs 6: 369-383
3. Alberts DS, Liu PY, Hanigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, Dubeshter B, Adelson MD and Hoskins WJ (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950-1956
4. Ben-Josef E, Mesina J, Shaw LM, Bonner HS, Shamsa F and Porter AT (1995) Topical application of WR-2721 achieves high concentrations in the rectal wall. Radiation Res 143: 107-110
5. Betticher DC, Anderson H, Ranson M, Meeley K, Oster W and Thatcher N (1995) Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small cell lung cancer. A randomized phase II study. Br J Cancer 72: 1551-1555
6. Bogliun G, Marzorati L, Marzola M, Miceli MD, Cantu MG and Cavaletti G (1996) Neurotoxicity of cisplatin +/-reduced glutathione in the first-line treatment of advanced ovarian cancer. Int J Gynaecol Cancer 6: 415-419
7. Brizel D, Sauer M, Wannenmacher M, Henke M, Eschwege F and Wasserman T (1998) Randomized phase III trial of radiation +/-amifostine in patients with head and neck cancer. Proc Am Soc Clin Oncol 17: Abstract # 1487.
8. Budd GT (1996) Amifostine and chemotherapy-related thrombocytopenia. Semin Oncol 23: 49-52
9. Budd GT, Bukowski RM, Adelstein D, Pelley R, Olencki T, Petrus JV, McLain D, Conlon J, Kurman M, Capizzi RL and Ganapathi R (1996) Mature results of a randomized trial of carboplatin and amifostine vs carboplatin alone in patients with advanced malignancies. Proc Am Soc Clin Oncol 15: (abstract) 1720
10. Buntzel J, Kuttner K, Frohlich D and Glatzel M (1998) Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 9: 505-509
11. Calabro-Jones PM, Fahey RC, Smoluk GD and Ward JF (1985) Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol 47: 23-27
12. Calabro-Jones PM, Aguilera JA, Ward JE, Smoluk GD and Fahey RC (1988) Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 48: 3634-3640
13. Capizzi RL and Oster W (1995) Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experience. Eur J Cancer 31A: 8-13
14. Delaney JP, Bonsack ME and Felemovicius I (1994) Radioprotection of the rat small intestine with topical WR-2721. Cancer 74: 2379-2384
15. De Wil R (1995) Four cycles of BEP versus an altering regime of PVB and BEP in patients with poor prognosis metastatic testicular non-seminoma. A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71: 1311-1314
16. DiPaola RS, Rodriguez R, Goodin S, Recio A, Orlick M, Mollman J, Bird S, Belsh JM, Schein PS, Aisner J, Schuchter LM (1998) Amifostine and dose-intense paclitaxel in patients with advanced malignancies. Cancer Therapeutics 1: 11-17
17. Di Re F, Bohm S, Oriana S, Spatti GB and Zunino F (1990) Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer. Cancer Chemother Pharmacol 25: 355-360
18. Di Re F, Bohm S, Oriana S, Spatti GB, Pirovano C, Tedeschi M and Zunino F (1993) High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Ann Oncol 4: 55-61
19. Dorr RT (1996) Cytoprotective agents for anthracyclines. Semin Oncol 23: 23-24
20. Douay L, Hu C, Giarratana M-C, Bouchet S, Conlon J, Capizzi RL and Gorin N-C (1995) Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood 86: 2849-2855
21. Dunn TA, Schmoll HJ, Grunwald V, Bokemeyer C and Casper J (1996) Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer. Anticancer Drugs 7: 795-799
22. Ercan MT, Aras T, Aktas A, Kaya S and Bekdik CF (1994) Accumulation of 99mTc-glutathione in head and neck tumors. Nuklearmedizin 33: 224-228
23. Glick JH, Glover DJ and Weiler C (1984) Phase I controlled trials of WR 2721 and cyclophosphamide. Int J Oncol Biol Phys 10: 1777-1780
24. Glover D, Glick JH, Weiler C, Fox K, Turrisi A and Klingerman MM (1986) Phase I/II trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys 12: 1509-1512
25. Grdina DJ, Kataoka Y and Basic I (1992) The radioprotector WR-2721 reduces neutron-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in mouse splenocytes when administered prior to or following irradiation. Carcinogenesis 13: 811-813
26. Grdina DJ, Shigematsu N, Dale P, Nemton GL, Aguilera JA and Fahey RC (1995) Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action. Carcinogenesis 16: 767-774
27. Gyenes G, Fornander T, Carlens P and Skovsgaard T (1996) Morbidity of ischemic heart disease in early breast cancer 15-20 years after adjuvant radiotherapy. Int J Rad Oncol Biol Phys 28: 1235-1241
28. Harners FPT, Brakkee JH, Cavalletti E, Tedeschi M, Marmonti L, Pezzoni G, Neijt JP and Gispen WH (1993) Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res 53: 544-549
29. 60Co γ-ray irradiation. Carcinogenesis 7: 665-668
30. Kaltenbach JA, Church MW, Blakley BW, McCaslin DL and Burgio DL (1997) Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster. Otolaryngol Head Neck Surg 117: 493-500
31. 60Co γ rays in mice. Int J Radiat Biol 61: 387-392
32. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D and Glick J (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized controlled trial in patients with advanced ovarian cancer. J Clin Oncol 14: 2101-2112
33. Korst AEC, Ecltink CM, Vermorken JB and Van de Vijgh WJF (1997) Pharmacokinetics of amifostine and its metabolites in patients. Eur J Cancer 33: 1425-1429
34. Leone R, Fracasso ME, Soresi E, Cimino G, Tedeschi M, Castoldi D, Monzani V, Colombi L, Usari T and Bernareggi A (1992) Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin. Cancer Chemother Pharmacol 29: 385-390
35. Lipschulz SE, Colan SD, Gelber RD, Peres-Atayde AR, Sallan and Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukaemia in childhood. N Engl J Med 324: 808-815
36. List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R and Capizzi R (1997) Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 90: 3364-3369
37. Liu TF, Liu Y, He S, Zhang Z and Kligerman MM (1992) The use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 69: 2820-2825
38. Liu SC, Murley JS, Woloschak G and Grdina DJ (1997) Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine. Carcinogenesis 18: 2457-2459
39. Locatelli MC, D'Antona A, Labianca R, Vinci M, Tedeschi M, Carcione R, Corbo A, Venturino P and Luporini G (1993) A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity. Tumori 79: 37-39
40. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M (1996) Cyclophosphamide and cisplatin compared with taxol and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 33: 1-6
41. Mangold DJ, Miller MA, Huelle BK, Sanchez-Barona DO, Swynnerton NF, Flechenstein L and Ludden TM (1989) Disposition of the radioprotector ethiofos in the rhesus monkey. Influence of route of administration. Drug Metab Dispos 17: 304-310
42. Meister A (1983) Selective modification of glutathione metabolism. Science 220: 472-477
43. Milas L, Hunter N, Stephens LC and Peters LJ (1984) Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid). Cancer Res 44: 5567-5569
44. Millar JL, McElwain TJ, Clutterhuck RD and Wist EA (1982) The modification of melphalan toxicity in tumour bearing mice by WR-2721. Am J Clin Oncol 5: 321-328
45. Mollman JE, Glover DJ, Hogan WM and Furman RE (1988) Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 61: 2192-2195
46. Montana GS, Anscher MS, Mansbach II CM, Daly N, Delannes M, Clarke-Pearson D and Gaydica F (1992) Topical application of WR-2721 to prevent radiation-induced proctosigmoiditis. Cancer 69: 2826-2830
47. Mori T, Nikaido O and Sugahara T (1984) Dephosphorylation of WR-2721 with mouse tissue homogenates. Int J Radiat Oncol Biol Phys 10: 1529-1531
48. Murley JS and Grdina DJ (1995) The effects of cycloheximide and WR-1065 on radiation-induced repair processes: a mechanism for chemoprevention. Carcinogenesis 16: 2699-2705
49. Murley JS, Constantinou A, Kamath NS and Grdina DJ (1997) WR-1065, an active metabolite of the cytoprotector amifostine, affects phosphorylation of topoisomerase II alpha leading to changes in enzyme activity and cell cycle progression in CHO AA8 cells. Cell Profil 30: 283-294
50. Nagy B and Grdina DJ (1986) Protective effects of WR-2721 against blcomycin and nitrogen mustard-induced mutagenicity in V76 cells. Int J Radiat Oncol Biol Phys 12: 1475-1478
51. Nagy B, Dale PJ and Grdina DJ (1986) Protection against cis diamminedichloroplatinum cytotoxicity and mutagenicity in V79 cells by WR-2721. Cancer Res 46: 1132-1135
52. Nooijen PT, Westphal JR, Eggermont AM, Schalkwijk C, Max R, De Waal RM and Ruiter DJ (1998) Endothelial P-selectin expression is reduced an advanced primary melanoma and melanoma metastasis. Am J Pathol 152: 679-682
53. Parnis FX, Coleman RE, Harper PG, Pickering D, Topham C, Whittington JR and Tedeschi M (1995) A randomised double-blind placebo controlled clinical trial assessing the tolerability and efficacy of glutathione as an adjuvant to escalating doses of cisplatin in the treatment of advanced ovarian cancer. Eur J Cancer 31A: 1721
54. Planting AST, Vermorken JB, Catimel G, De Mulder PHM, De Graeff A, Oster W, and Hoppener F (1996) Randomized phase II study of cisplatin with and without amifostine in patients with advanced head and neck cancer. Proc Am Soc Clin Oncol 15: abstract # 887
55. Poplin EA, LoRusso P, Lokich JJ (1994) Randomized clinical trial of mitomycin C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 33: 415-419
56. Romero FJ, Segura-Aguilar J, Monsalre E, Hermenegildo C, Nies E, Puertas FJ and Roma J (1990) Antioxidant and glutathione-related enzymatic activities in rat sciatic nerve. Neurotoxicol Teratol 12: 603-605
57. Rubin JS, Wadler S, Beitler JJ, Haynes H, Rozenblit A, McGill F, Goldberg G and Runowicz C (1995) Audiological findings in a phase I protocol investigating the effect of WR-2721, high dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma .J Laryngol Otol 109: 744-747
58. Sajjan AR, Hinchigeri SB and Datta KS (1991) Multiple forms of γ-glutamyl transpeptidase in human submandibular gland. Clin Chim Acta 197: 133-139
59. Schiller JH, Storer B and Berlin J (1996) Amifostine, cisplatin and vinblastine in metastatic non-small-cell lung cancer; a report of high response rates and prolonged survival. J Clin Oncol 14: 1913-1921
60. Schwindt EA, Collet AM, Mendez AE, Cabrini RL and Itoiz ME (1992) The first normal oral epithelium which γ-glutamyl transpeptidase activity has been detected. Histochem J 24: 964-968
61. Shapiro CL and Henderson IC (1994) Late cardiac effects of adjuvant therapy: too soon to tell? Ann Oncol 5: 196-198
62. Shaw LM, Turrisi AT and Glover DJ (1986) Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys 12: 1501-1504
63. Shaw LM, Bonner H, Nakashima H and Lieberman R (1994) Evidence for saturable metabolism. Proc Am Soc Clin Oncol 13: abstract # 144
64. Shpall EJ, Stemmer SM, Hami L, Franklin WA, Shaw L, Bonner HS, Bearman SI, Peters WP, Bast RC, McCulloch W, Capizzi R, Mitchell E, Schein PS and Jones RB (1994) Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxy-cyclophosphamide purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 83: 3132-3137
65. Smoluk GD, Fahey RC, Calabro-Jones PM, Aguilera JA and Ward JF (1988) Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection. Cancer Res 48: 3641-3647
66. Smyth I, Bowman A, Perren T, Wilkinson P, Prescott R, Quinn KJ and Tedeschi M (1997) Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind randomised trial. Ann Oncol 8: 569-573
67. Steinherz LJ and Yahalom J (1993) Cardiac complications of cancer therapy. In Cancer Principles & Practice of Oncology, De Vita VT, Hellman S and Rosenberg SA (eds), pp. 2370-2385. Lippincott: Philadelphia
68. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR and Gams RA (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15: 1318-1332
69. Taylor CW, Wang LM, List AF, Fernandes D, Paine-Murrieta GD, Johnson CS and Capizzi RI, (1997) Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur J Cancer 33: 1693-1698
70. μP NMR characterization of the reaction between antitumor platinum agents and the phosphorothioate chemoprotective agent S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721). Biochem Pharmacol 50: 1413-1419
71. Treskes M, Holwerda U, Klein J, Pinedo HM and Van der Vijgh WJF (1991) The chemical reactivity of the modulating agent WR 2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin. Biochem Pharmacol 42: 2125-2130
72. Treskes M, Boven E, Van de Loosdrecht AA and Wijffels JFAM (1994) Effects of the modulating agent WR-2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer 30A: 183-187
73. Utley JF, Marlowe C and Waddell WJ (1976) Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse. Radiat Res 68: 284-291
74. Valeriote F and Tolen S (1982) Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 42: 4330-4331
75. Van der Vijgh WJ and Korst AE (1996) Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo. Eur J Cancer 32A(4): S26-S30.
76. Washburn LC, Rafter JJ, Hayes RL and Yuhas JM (1976) Prediction of the effective radioprotective dose of WR-2721 in humans through an interspecies tissue distribution study. Radiat Res 66: 100-105
77. Wasserman TH, Philips TL, Ross G and Kane LJ (1981) Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trials 4: 3-6
78. Weiss JF (1997) Pharmacologic approaches to protection against radiation-induced lethality and other damage. Environ Health Perspect 105S (suppl 6): 1473-1478
79. Wooley PV, Ayoob MJ and Smith FP (1983) Clinical trial of the effect of S-2(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide. J Clin Oncol 5: 198-203
80. Yuhas JM (1980) Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 40: 1519-1524
81. Zunino F, Prates G, Micheloni A, Cavalleti E, Sala F and Tofanetti O (1989) Protective effect of reduced glutathione against cisplatin induced renal and systemic toxicity and its influence on the therapeutic activity of the anti-tumour drug. Chem Biol Interact 70: 89-101